Shanghai RAAS to be acquired by Haier Bio in stock swap

Shanghai RAAS Blood Products (SZSE:002252) announced a trading halt starting December 23, 2024, pending a major asset restructuring. The company's controlling shareholder, informed RAAS that it is planning a stock swap acquisition by Haier Bio. Haier Bio will issue A-shares to all Shanghai RAAS shareholders, effectively merging the companies. The plan also includes raising additional capital alongside the merger. A non-binding agreement has been signed, and the deal is still under negotiation. The trading halt is expected to last no more than 10 trading days. More details are expected upon finalization of the agreement. Haier Bio released a concurrent announcement with further information. Investors are advised to exercise caution.